Teva names new CEO

Share this article:

The rumors are true: Erez Vigodman is Teva Pharmaceutical's new president and CEO. The Jerusalem, Israel, company said in the Thursday announcement that he will officially take on the roles February 11.

The appointment will end a public relations rough patch which included the October announcement that Teva was laying off 10% of its staff to limit the impact of generic Copaxone, which was soon followed by a public “was he fired or was he pushed?” feud that saw then-CEO Jeremy Levin leave the company. Eyal Desheh stepped in as acting president and CEO. He will now slide back into his role as group EVP and CFO.

Vigodman was already on Teva's board and currently heads up the generic agrochemical company Makhteshim Agan Industries. Teva said in a statement that Vigodman will stay with MAI until February 6.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters